pH-Triggered Copper-Free Click Reaction-Mediated Micelle Aggregation for Enhanced Tumor Retention and Elevated Immuno–Chemotherapy against Melanoma
Source abstract
Abstract
Natural killer (NK) cell-based immunotherapy presents a promising antitumor strategy and holds potential for combination with chemotherapy. However, the suppressed NK cell activity and poor tumor retention of therapeutics hinder the efficacy. To activate NK cell-based immuno–chemotherapy and enhance the tumor retention, we proposed a pH-responsive self-aggregated nanoparticle for the codelivery of chemotherapeutic doxorubicin (DOX) and the transforming growth factor-β (TGF-β)/Smad3 signaling pathway inhibitor SIS3. Polycaprolactone-poly(ethylene glycol) (PCL-PEG2000) micelles modified with dibenzylcyclooctyne (DBCO) or azido (N3) and coated with acid-cleavable PEG5000 were established. This nanoplatform, namely, M-DN@DOX/SIS3, could remain well dispersed in the neutral systemic circulation, while quickly respond to the acidic tumor microenvironment and intracellular lysosomes, triggering copper-free click reaction-mediated aggregation, leading to the increased tumor accumulation and reduced cellular efflux. In addition, the combination of DOX with SIS3 facilitated by the aggregation strategy resulted in potent inhibition of melanoma tumor growth and significantly increased NK cells, NK cell cytokines, and antitumor T cells in the tumor. Taken together, our study offered a new concept of applying copper-free click chemistry to achieve nanoparticle aggregation and enhance tumor retention, as well as a promising new combined tumor treatment approach of chemotherapy and immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune Cell Function and Interaction · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, People’s Republic of China
Funding
China Agricultural Research System · National Natural Science Foundation of China
References (65)
Show source-provided references
1. 10.1016/j.canlet.2014.03.01310.1016/j.canlet.2014.03.013 ↗
2. 10.2174/1381612811319999049310.2174/13816128113199990493 ↗
3. 10.3390/cancers603176910.3390/cancers6031769 ↗
4. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
5. 10.1016/j.jcyt.2015.03.60510.1016/j.jcyt.2015.03.605 ↗
6. 10.1016/j.coi.2015.12.00310.1016/j.coi.2015.12.003 ↗
7. 10.1016/j.canlet.2019.11.00910.1016/j.canlet.2019.11.009 ↗
8. 10.1038/nrc323910.1038/nrc3239 ↗
9. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
10. 10.3389/fphar.2017.0056110.3389/fphar.2017.00561 ↗
11. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
12. 10.1002/anie.20180488210.1002/anie.201804882 ↗
13. 10.1016/j.biomaterials.2014.05.07610.1016/j.biomaterials.2014.05.076 ↗
14. 10.1016/j.canlet.2016.05.02510.1016/j.canlet.2016.05.025 ↗
15. 10.1038/s41573-018-0007-y10.1038/s41573-018-0007-y ↗
16. 10.3389/fimmu.2018.0204110.3389/fimmu.2018.02041 ↗
17. 10.1038/ni.351810.1038/ni.3518 ↗
18. 10.1126/science.285.5428.72710.1126/science.285.5428.727 ↗
19. Pende D. · Cancer Res. · 2002 · 62 · 6178
20. 10.1073/pnas.96.12.687910.1073/pnas.96.12.6879 ↗
21. 10.1182/blood-2005-04-135110.1182/blood-2005-04-1351 ↗
22. 10.1002/eji.20032470510.1002/eji.200324705 ↗
23. 10.1002/immu.20031001210.1002/immu.200310012 ↗
24. 10.1073/pnas.073064010010.1073/pnas.0730640100 ↗
25. 10.4049/jimmunol.172.12.733510.4049/jimmunol.172.12.7335 ↗
26. 10.1158/0008-5472.CAN-04-162710.1158/0008-5472.CAN-04-1627 ↗
27. 10.1093/brain/awl20510.1093/brain/awl205 ↗
28. 10.1038/ncomms1467710.1038/ncomms14677 ↗
29. 10.1371/journal.pone.019135810.1371/journal.pone.0191358 ↗
30. 10.1158/1078-0432.CCR-16-174310.1158/1078-0432.CCR-16-1743 ↗
31. 10.4049/jimmunol.181.6.378410.4049/jimmunol.181.6.3784 ↗
32. 10.1038/nnano.2008.11410.1038/nnano.2008.114 ↗
33. 10.1002/adma.20160662810.1002/adma.201606628 ↗
34. 10.1126/science.109583310.1126/science.1095833 ↗
35. 10.1016/j.addr.2006.09.00910.1016/j.addr.2006.09.009 ↗
36. 10.1002/smll.20120139010.1002/smll.201201390 ↗
37. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
38. 10.1021/acsnano.5b0201710.1021/acsnano.5b02017 ↗
39. 10.1016/j.jconrel.2018.04.05310.1016/j.jconrel.2018.04.053 ↗
40. 10.1021/acsami.7b0230310.1021/acsami.7b02303 ↗
41. 10.1021/acsnano.6b0507010.1021/acsnano.6b05070 ↗
42. 10.1021/acsami.8b0295410.1021/acsami.8b02954 ↗
43. 10.1016/j.actbio.2019.03.02210.1016/j.actbio.2019.03.022 ↗
44. 10.1021/ja100014q10.1021/ja100014q ↗
45. 10.1021/ml300236m10.1021/ml300236m ↗
46. 10.1002/anie.20120670310.1002/anie.201206703 ↗
47. 10.1021/acs.accounts.8b0019510.1021/acs.accounts.8b00195 ↗
48. 10.1038/nbt89610.1038/nbt896 ↗
49. 10.1038/s41592-019-0530-810.1038/s41592-019-0530-8 ↗
50. 10.1016/j.jconrel.2016.03.00110.1016/j.jconrel.2016.03.001 ↗
51. 10.1021/acsnano.7b0805110.1021/acsnano.7b08051 ↗
52. 10.2174/1381612811319999049310.2174/13816128113199990493 ↗
53. 10.1038/nrc278910.1038/nrc2789 ↗
54. 10.1615/CritRevTherDrugCarrierSyst.v19.i1.1010.1615/CritRevTherDrugCarrierSyst.v19.i1.10 ↗
55. 10.1002/jps.2246110.1002/jps.22461 ↗
56. 10.1126/scitranslmed.300138510.1126/scitranslmed.3001385 ↗
57. 10.1016/j.jconrel.2004.12.01810.1016/j.jconrel.2004.12.018 ↗
58. 10.1016/j.jconrel.2006.09.00710.1016/j.jconrel.2006.09.007 ↗
59. 10.1002/jps.2220010.1002/jps.22200 ↗
60. 10.1021/acs.molpharmaceut.8b0046510.1021/acs.molpharmaceut.8b00465 ↗
61. 10.1021/nn402201w10.1021/nn402201w ↗
62. 10.1016/j.cell.2008.07.00110.1016/j.cell.2008.07.001 ↗
63. 10.1016/j.immuni.2019.03.02410.1016/j.immuni.2019.03.024 ↗
64. 10.4049/jimmunol.174.8.448010.4049/jimmunol.174.8.4480 ↗
65. 10.1101/cshperspect.a02847210.1101/cshperspect.a028472 ↗